IVF-M HP Use In Pregnancy & Lactation

1) This product should not be given during pregnancy or to lactating mothers.
2) The relationship between treatment of luteinizing hormone and the birth of congenitally defective child has not been established yet. But according to the epidemiological investigation, between the women who had delivered babies with congenital defects in heart and limbs and so on and the control group, there was a significant difference in the frequency of use of LH and/or LH∙FSH during the early stage of pregnancy.
3) The prevalence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. This is thought to be due to differences in parental characteristics (e.g. maternal age, sperm characteristics) and multiple pregnancies.
The incidence of pregnancy wastage by miscarriage or abortion caused by this product is comparable in women with other fertility problems.
Multiple pregnancy, especially high order, carries an increased risk of adverse maternal and perinatal outcomes.